Surgery Partners' (SGRY) Buy Rating Reaffirmed at Benchmark

Surgery Partners (NASDAQ:SGRY - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Benchmark in a report released on Monday,Benzinga reports. They currently have a $35.00 price target on the stock. Benchmark's price target points to a potential upside of 62.94% from the company's previous close.

A number of other equities analysts have also weighed in on SGRY. Macquarie decreased their target price on Surgery Partners from $34.00 to $33.00 and set an "outperform" rating for the company in a research report on Tuesday, March 11th. Royal Bank of Canada reissued an "outperform" rating and set a $35.00 price objective on shares of Surgery Partners in a report on Tuesday, March 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.75.

Surgery Partners Stock Down 1.6 %

SGRY stock traded down $0.36 during trading on Monday, hitting $21.48. 846,186 shares of the stock traded hands, compared to its average volume of 1,096,933. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -44.75, a price-to-earnings-growth ratio of 19.21 and a beta of 2.40. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. Surgery Partners has a 1 year low of $19.50 and a 1 year high of $33.97. The firm's 50 day moving average is $23.07 and its two-hundred day moving average is $24.10.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.01. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The company had revenue of $864.40 million during the quarter, compared to the consensus estimate of $828.09 million. On average, sell-side analysts anticipate that Surgery Partners will post 0.67 EPS for the current year.

Insider Buying and Selling at Surgery Partners

In related news, insider Marissa Brittenham sold 3,156 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $24.09, for a total transaction of $76,028.04. Following the completion of the transaction, the insider now directly owns 63,408 shares in the company, valued at approximately $1,527,498.72. The trade was a 4.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO David T. Doherty sold 13,641 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $25.61, for a total transaction of $349,346.01. Following the sale, the chief financial officer now owns 108,862 shares in the company, valued at approximately $2,787,955.82. The trade was a 11.14 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 106,622 shares of company stock valued at $2,717,860. Company insiders own 2.30% of the company's stock.

Hedge Funds Weigh In On Surgery Partners

A number of hedge funds have recently made changes to their positions in SGRY. KBC Group NV lifted its holdings in Surgery Partners by 66.1% in the 4th quarter. KBC Group NV now owns 3,962 shares of the company's stock worth $84,000 after purchasing an additional 1,577 shares in the last quarter. State of Wyoming lifted its holdings in shares of Surgery Partners by 94.4% in the fourth quarter. State of Wyoming now owns 4,002 shares of the company's stock worth $85,000 after buying an additional 1,943 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Surgery Partners by 12.1% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,296 shares of the company's stock worth $91,000 after acquiring an additional 465 shares during the last quarter. GAMMA Investing LLC grew its stake in Surgery Partners by 7,902.7% during the first quarter. GAMMA Investing LLC now owns 8,883 shares of the company's stock valued at $211,000 after acquiring an additional 8,772 shares in the last quarter. Finally, MeadowBrook Investment Advisors LLC increased its holdings in Surgery Partners by 16.6% in the 4th quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company's stock valued at $218,000 after acquiring an additional 1,460 shares during the last quarter.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.